Impact of Decitabine Conditioning on Allo‐HSCT Outcomes in AML and Intermediate‐to‐High‐Risk MDS Patients in Remission
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remains the sole curative option for myeloid malignancies, though high toxicity from conditioning regimens and complications like graft‐versus‐host disease (GVHD) limit its success. The potential benefit of incorporat...
Saved in:
| Main Authors: | Shuling Yu, Wanchuan Zhuang, Shengfa Gao, Tongyu Li, Xiao Yan, Guifang Ouyang, Ping Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.71081 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
by: Christoforos K. Vaxevanis, et al.
Published: (2023-12-01) -
Comparative Study of Mycophenolate Mofetil and Methotrexate in Graft-Versus-Host Disease Prophylaxis in Adult Recipients of Related and Unrelated Allo-HSCT
by: IS Moiseev, et al.
Published: (2018-12-01) -
Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trialResearch in context
by: Qifa Liu, et al.
Published: (2025-08-01) -
Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML
by: Brian J. Ball, et al.
Published: (2025-07-01) -
TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies
by: Marwah M. Albakri, et al.
Published: (2025-08-01)